Back to mobile site

Concert Pharma (CNCE) Reports Clinical Hold on CTP-543 Phase 2A Trial

May 17, 2017 7:32 AM EDT Send to a Friend
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has received notice from the U.S. Food and Drug Administration (FDA) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login